search button
Open Access

Mutations in the helix αC of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines

  • Authors:
    • Arturo Valle‑Mendiola
    • Ricardo Bustos‑Rodríguez
    • Vanihamin Domínguez‑Melendez
    • Octavio Zerecero‑Carreón
    • Adriana Gutiérrez‑Hoya
    • Benny Weiss‑Steider
    • Isabel Soto‑Cruz

  • View Affiliations

  • Published online on: January 5, 2022     https://doi.org/10.3892/ol.2022.13191
  • Article Number: 71

  • Copyright: © Valle‑Mendiola et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The EGFR is a protein that belongs to the ErbB family of tyrosine kinase receptors. The EGFR is often overexpressed in human carcinomas. Amplification of the EGFR gene and mutations in the EGFR tyrosine kinase domain occur in patients with cancer. In cervical cancer, the expression level of the EGFR protein appears to directly associate with human papillomavirus infection. Our previous research demonstrated that in the cervical cancer cell lines, CALO and INBL, the EGFR is non‑phosphorylated. The aim of the current study was to analyze the catalytic activity of the isolated EGFR and the presence of mutations in the control region αC. Catalytic activity was assessed by a universal in vitro kinase assay using polyGluTyr as a substrate, and the proteins were visualized by western blotting. For mutation analysis, DNA from CALO and INBL cell lines was isolated, and PCR was used to amplify the exons corresponding to the helix αC in the EGFR. The PCR products were visualized by agarose gel electrophoresis. The bands were isolated using a Zymoclean Gel DNA Recovery kit and directly sequenced. The EGFR, which was isolated and analyzed using the in vitro kinase assay, had catalytic activity. The receptor contained some mutations in the helix αC of the catalytic domain in both cell lines. The observed changes in the amino acid sequence may induce a different spatial arrangement and, therefore, a different conformation, which may confer different activities to this receptor. Thus, it was concluded that non‑phosphorylated EGFR has catalytic activity, and it bears some amino acid changes in the helix αC of the catalytic domain in the CALO and INBL cells. These results suggest that the EGFR may function as an activator of other ErbB family receptors in these cervical cancer cells.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 23 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Valle‑Mendiola A, Bustos‑Rodríguez R, Domínguez‑Melendez V, Zerecero‑Carreón O, Gutiérrez‑Hoya A, Weiss‑Steider B and Soto‑Cruz I: Mutations in the helix αC of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines. Oncol Lett 23: 71, 2022.
APA
Valle‑Mendiola, A., Bustos‑Rodríguez, R., Domínguez‑Melendez, V., Zerecero‑Carreón, O., Gutiérrez‑Hoya, A., Weiss‑Steider, B., & Soto‑Cruz, I. (2022). Mutations in the helix αC of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines. Oncology Letters, 23, 71. https://doi.org/10.3892/ol.2022.13191
MLA
Valle‑Mendiola, A., Bustos‑Rodríguez, R., Domínguez‑Melendez, V., Zerecero‑Carreón, O., Gutiérrez‑Hoya, A., Weiss‑Steider, B., Soto‑Cruz, I."Mutations in the helix αC of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines". Oncology Letters 23.2 (2022): 71.
Chicago
Valle‑Mendiola, A., Bustos‑Rodríguez, R., Domínguez‑Melendez, V., Zerecero‑Carreón, O., Gutiérrez‑Hoya, A., Weiss‑Steider, B., Soto‑Cruz, I."Mutations in the helix αC of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines". Oncology Letters 23, no. 2 (2022): 71. https://doi.org/10.3892/ol.2022.13191